• 1. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283

Professional Introduction to (4-Methylisoxazol-5-YL)methanol (CAS No. 1607024-83-8)

(4-Methylisoxazol-5-YL)methanol, with the chemical formula C?H?NO? and CAS number 1607024-83-8, is a significant compound in the field of organic chemistry and pharmaceutical research. This compound belongs to the isoxazole class, which is known for its diverse biological activities and applications in medicinal chemistry. The structural features of (4-Methylisoxazol-5-YL)methanol make it a valuable intermediate in the synthesis of various pharmacologically active molecules.

Theisoxazolering system in (4-Methylisoxazol-5-YL)methanol is characterized by a five-membered heterocyclic ring containing an oxygen atom and a nitrogen atom. This unique arrangement imparts distinct electronic and steric properties to the molecule, making it a versatile scaffold for drug discovery. The presence of amethylgroup at the 4-position and a hydroxymethyl group at the 5-position further enhances its reactivity and potential utility in synthetic chemistry.

In recent years, there has been growing interest in exploring the pharmacological potential of isoxazole derivatives. Research has demonstrated that compounds containing the isoxazole moiety exhibit a wide range of biological activities, including anti-inflammatory, antimicrobial, and anticancer properties. (4-Methylisoxazol-5-YL)methanol, being a simple yet functional derivative, has been investigated for its possible role in these therapeutic areas.

One of the most compelling aspects of (4-Methylisoxazol-5-YL)methanol is its role as a building block in the synthesis of more complex molecules. For instance, researchers have utilized this compound to develop novel inhibitors targeting specific enzymes involved in cancer progression. The hydroxymethyl group at the 5-position provides a reactive site for further functionalization, allowing chemists to attach various pharmacophores and optimize biological activity.

Recent studies have highlighted the importance of (4-Methylisoxazol-5-YL)methanol in the development of kinase inhibitors. Kinases are enzymes that play crucial roles in cell signaling pathways, and their dysregulation is often associated with various diseases, particularly cancer. By incorporating the isoxazole ring into kinase inhibitors, researchers aim to enhance binding affinity and selectivity, thereby improving therapeutic efficacy. (4-Methylisoxazol-5-YL)methanol has been shown to serve as an effective precursor in these efforts.

Another area where (4-Methylisoxazol-5-YL)methanol has shown promise is in the field of immunomodulation. Immunomodulatory drugs are designed to modulate immune responses, making them useful in treating autoimmune diseases and enhancing vaccine efficacy. The structural features of this compound allow it to interact with various immune receptors and signaling pathways, potentially leading to novel immunotherapeutic strategies.

The synthesis of (4-Methylisoxazol-5-YL)methanol involves multi-step organic reactions that highlight its synthetic versatility. Typically, it is prepared through condensation reactions involving appropriate precursors such as hydroxymethyl-substituted ketones or aldehydes with isocyanates or other nucleophiles. These reactions often require careful optimization to ensure high yield and purity, which are critical for pharmaceutical applications.

Advances in synthetic methodologies have also enabled the preparation of derivatives of (4-Methylisoxazol-5-YL)methanol with tailored properties. For example, modifications at the 3-position or other positions on the isoxazole ring can introduce additional functional groups that enhance solubility, metabolic stability, or target specificity. Such modifications are essential for developing drug candidates that meet stringent pharmacokinetic and pharmacodynamic requirements.

Computational chemistry and molecular modeling have played a significant role in understanding the interactions between (4-Methylisoxazol-5-YL)methanol and biological targets. These tools allow researchers to predict binding affinities, identify key interaction sites, and design optimized analogs with improved properties. Such computational approaches complement experimental efforts and accelerate the drug discovery process.

In conclusion, (4-Methylisoxazol-5-YL)methanol (CAS No. 1607024-83-8) is a versatile compound with significant potential in pharmaceutical research. Its unique structural features make it a valuable intermediate for synthesizing bioactive molecules targeting various diseases. Ongoing research continues to explore its applications in oncology, immunology, and other therapeutic areas, underscoring its importance as a building block in medicinal chemistry.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)